Signaturefd LLC Raises Stock Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Signaturefd LLC raised its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 5.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,511 shares of the company’s stock after buying an additional 125 shares during the quarter. Signaturefd LLC’s holdings in Neurocrine Biosciences were worth $331,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in NBIX. Assenagon Asset Management S.A. lifted its stake in Neurocrine Biosciences by 120.6% in the third quarter. Assenagon Asset Management S.A. now owns 584,539 shares of the company’s stock valued at $65,761,000 after buying an additional 319,564 shares during the last quarter. Westfield Capital Management Co. LP lifted its stake in Neurocrine Biosciences by 73.0% in the third quarter. Westfield Capital Management Co. LP now owns 649,292 shares of the company’s stock valued at $73,045,000 after buying an additional 273,952 shares during the last quarter. Jacobs Levy Equity Management Inc. lifted its stake in Neurocrine Biosciences by 59.0% in the third quarter. Jacobs Levy Equity Management Inc. now owns 692,374 shares of the company’s stock valued at $77,892,000 after buying an additional 256,920 shares during the last quarter. Jennison Associates LLC lifted its stake in Neurocrine Biosciences by 86.0% in the third quarter. Jennison Associates LLC now owns 409,475 shares of the company’s stock valued at $46,066,000 after buying an additional 189,345 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC lifted its stake in Neurocrine Biosciences by 81.9% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 410,103 shares of the company’s stock valued at $54,035,000 after buying an additional 184,660 shares during the last quarter. Hedge funds and other institutional investors own 92.59% of the company’s stock.

Neurocrine Biosciences Stock Performance

Neurocrine Biosciences stock opened at $137.76 on Friday. The firm has a market capitalization of $13.71 billion, a price-to-earnings ratio of 56.93 and a beta of 0.25. Neurocrine Biosciences, Inc. has a fifty-two week low of $89.04 and a fifty-two week high of $148.37. The stock’s fifty day moving average is $136.56 and its two-hundred day moving average is $127.69.

Neurocrine Biosciences (NASDAQ:NBIX) last posted its earnings results on Wednesday, February 7th. The company reported $1.44 earnings per share for the quarter, beating the consensus estimate of $1.13 by $0.31. The company had revenue of $515.20 million for the quarter, compared to analyst estimates of $518.52 million. Neurocrine Biosciences had a return on equity of 12.85% and a net margin of 13.23%. Neurocrine Biosciences’s revenue was up 25.0% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.88 earnings per share. As a group, sell-side analysts forecast that Neurocrine Biosciences, Inc. will post 4.84 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on the company. Needham & Company LLC reiterated a “hold” rating on shares of Neurocrine Biosciences in a research note on Tuesday. StockNews.com upgraded Neurocrine Biosciences from a “buy” rating to a “strong-buy” rating in a research note on Thursday, February 8th. JPMorgan Chase & Co. upped their price target on Neurocrine Biosciences from $148.00 to $158.00 and gave the stock an “overweight” rating in a research note on Wednesday, March 20th. Wells Fargo & Company upgraded Neurocrine Biosciences from an “equal weight” rating to an “overweight” rating and upped their price target for the stock from $140.00 to $170.00 in a research note on Wednesday. Finally, Mizuho upped their price target on Neurocrine Biosciences from $116.00 to $140.00 and gave the stock a “neutral” rating in a research note on Thursday, February 8th. Six investment analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $142.38.

Insider Buying and Selling at Neurocrine Biosciences

In related news, insider Eric Benevich sold 19,818 shares of the stock in a transaction on Monday, April 15th. The stock was sold at an average price of $133.36, for a total transaction of $2,642,928.48. Following the sale, the insider now owns 40,778 shares of the company’s stock, valued at $5,438,154.08. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In related news, insider Eric Benevich sold 19,818 shares of the stock in a transaction on Monday, April 15th. The stock was sold at an average price of $133.36, for a total transaction of $2,642,928.48. Following the sale, the insider now owns 40,778 shares of the company’s stock, valued at $5,438,154.08. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Kevin Charles Gorman sold 2,707 shares of the stock in a transaction on Wednesday, January 31st. The shares were sold at an average price of $140.69, for a total value of $380,847.83. Following the sale, the chief executive officer now directly owns 502,188 shares in the company, valued at approximately $70,652,829.72. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 186,994 shares of company stock valued at $25,806,409. Insiders own 4.40% of the company’s stock.

Neurocrine Biosciences Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.